<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Corixa Corporation
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.001 Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
21887F100
--------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, SmithKline Beecham Corporation
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
October 6, 1999
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /.
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
This Amendment No. 1 amends and supplements the Statement of Schedule 13D
electronically filed with the Securities and Exchange Commission (the
"Commission") on February 5, 1999 (the "Initial Statement").
The undersigned hereby amends and supplements Item 5 of the Initial Statement to
include the following information (capitalized terms used herein without
definition shall have the same meaning as set forth in the Initial Statement.
<PAGE> 2
SCHEDULE 13D
CUSIP NO. 21887F100 PAGE 2 OF 7 PAGES
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
S.R. One, Limited
23-1729901
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Pennsylvania Business Trust
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 530,427
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
530,427
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
530,427
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
<PAGE> 3
SCHEDULE 13D
CUSIP NO. 21887F100 PAGE 3 OF 7 PAGES
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham plc
98-0101920
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
England
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 427,807
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
427,807
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
427,807
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
2.0%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE> 4
SCHEDULE 13D
CUSIP NO. 21887F100 PAGE 4 OF 7 PAGES
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
SmithKline Beecham Biologicals Manufacturing s.a.
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) /x/
(b) / /
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Belgium
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES 185,922
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
185,922
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
185,922
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
.9%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
<PAGE> 5
PAGE 5 OF 7 PAGES
Item 1. Security and Issuer.
Item 2. Identity and Background.
(a) SmithKline Beecham Biologicals Manufacturing s.a. (SBBM), a
company organized under the laws of Belgium, engages in commercial, industrial
and financial activities relating to real and personal property for SmithKline
Beecham's worldwide vaccines business, SmithKline Beecham Biologicals.
Collectively, SRO, SBplc and SBBM are sometimes
referred to as the "Group".
(b) The principal business address for SBBM is:
Rue de l'Institut 89
B-1330 Rixensart
BELGIUM
(c) Information concerning the Group is set forth in response to
Item 2(a) above.
(d) During the last five years, the Group has not been convicted
in a criminal proceeding, excluding traffic violations or similar misdemeanors.
(e) During the last five years the Group was not a party to a
civil proceeding of a judicial or administrative body of competent jurisdiction
and as a result thereof subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to Federal
or State securities laws or finding any violation with respect to such laws.
(f) Not applicable.
<PAGE> 6
PAGE 6 OF 7 PAGES
Item 3. Source and Amount of Funds or Other Consideration.
Item 4. Purpose of Transaction.
The Group intends to review from time to time the business affairs and
financial position of the Issuer. Based on such evaluation and review, as well
as general economic and industry conditions existing at the time and the Group's
own financial plans, the Group may consider from time to time various
alternative courses of action. Such actions may include the acquisition of
additional shares through open market purchases, privately negotiated
transactions or otherwise. Alternatively, such actions may involve the sale of
all or a portion of the shares in the open market, in privately negotiated
transactions, through public offering or otherwise. All of the securities
acquired have been purchases for investment purposes.
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
<TABLE>
<CAPTION>
Registered Name No. of Shares Percent
<S> <C> <C>
SRO 505,050
SRO 25,377 * 2.5%
SBplc 427,807 2.0%
SBBM 185,922 * 0.9%
--------- ----
1,144,156 5.4%
</TABLE>
*On October 6, 1999, Ribi Immunochem Research Inc. (Ribi) merged into Issuer.
SRO and SBBM received an aggregate amount of 211,299 shares of Issuer's Common
stock in exchange for their Ribi shares as a result of this merger.
Item 6. Contracts, Arrangements, Understandings or
Relationship With respect to Securities of the Issuer.
Item 7. Materials to be Filed as Exhibits.
Exhibit 1. Joint Filing Agreement dated as of October 4, 2000
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, the undersigned certifies that the information set forth in the
Statement is true, correct and complete.
DATED: October 11, 2000 S.R. ONE, LIMITED
By: /s/
Donald F. Parman
Vice President
and Secretary
<PAGE> 7
PAGE 7 OF 7 PAGES
EXHIBIT 1
The undersigned hereby agree, pursuant to Rule 13d-1(f)(1) under Section
13(d) of the Securities Exchange Act of 1934, as amended, that (1) they shall
cause a single Schedule 13D to be filed on behalf of each party in respect
of their ownership interests in the Common Stock of Corixa Corporation and (2)
S.R. One, Limited shall be authorized to sign said Schedule 13D and any
amendments thereto on behalf of each member of the Group.
S.R. ONE, LIMITED
By: /s/
Donald F. Parman
Vice President
and Secretary
SMITHKLINE BEECHAM plc
By: /s/
Name: S. Wilbraham
Title: Assistant
Sectretary
SMITHKLINE BEECHAM BIOLOGICALS
MANUFACTURING s.a.
By: /s/
Name: Jean-Pierre Suin
Title: Vice President Director
Finances/I.R.
DATED: October 4, 2000 Management Services
